---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-074719"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:02:05.265143+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Protagonist Q2 net loss $34.8M; icotrokinra NDA filed, rusfertide NDA on track

## Summary
- Net loss $34.8M ($0.55/share) vs $30.6M in Q2 2024; license revenue $5.5M from Takeda.
- Cash $673M as of June 30, sufficient for runway through at least end 2028.
- NDA for icotrokinra (moderate-to-severe plaque psoriasis) submitted to FDA in July.
- Rusfertide NDA for polycythemia vera expected Q4 2025; Phase 3 VERIFY data presented at ASCO.
- Pipeline: PN-477 oral/subcutaneous triple agonist for obesity selected; PN-881 IL-17 antagonist.

## SEC filing metadata
- accession: 0001104659-25-074719
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465925074719/0001104659-25-074719-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465925074719/tm2522652d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-074719
- JSON: https://secwatch.observer/filing/0001104659-25-074719.json
- Plain text: https://secwatch.observer/filing/0001104659-25-074719.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.